Plain-English translation of NCT06984627 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing rilzabrutinib, a new medication, to see if it can safely and effectively treat Graves' disease—a condition where your immune system attacks your thyroid gland, causing it to produce too much hormone. The study will compare two different doses of the medication to understand which works best and how safe it is. About 30 adults with this condition will participate.
Currently, treatment options for Graves' disease are limited and don't work well for everyone. Researchers believe this new treatment may offer patients a better way to control their overactive thyroid and related symptoms, including eye problems that sometimes occur with this disease.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic up to 13 times over about 24 weeks total. First, you'll have a screening visit (up to 4 weeks) where doctors confirm your diagnosis and check your overall health. Then you'll take the medication for up to 16 weeks, with regular clinic visits to check how well it's working and monitor for any side effects. Finally, you'll have a follow-up visit 4 weeks after stopping the medication to make sure you're doing well.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
Argentina
Canada